Home » Stocks » Intellia Therapeutics

Intellia Therapeutics, Inc. (NTLA)

Stock Price: $24.59 USD -1.18 (-4.58%)
Updated Oct 20, 2020 11:23 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.44B
Revenue (ttm) 50.73M
Net Income (ttm) -116.11M
Shares Out 58.74M
EPS (ttm) -2.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $24.59
Previous Close $25.77
Change ($) -1.18
Change (%) -4.58%
Day's Open 25.73
Day's Range 24.27 - 26.35
Day's Volume 261,234
52-Week Range 9.18 - 27.07

More Stats

Market Cap 1.44B
Enterprise Value 1.03B
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date n/a
Shares Outstanding 58.74M
Float 49.08M
EPS (basic) -2.31
EPS (diluted) -2.30
FCF / Share -0.78
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11.94M
Short Ratio 13.38
Short % of Float 24.32%
Beta 1.68
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 28.47
PB Ratio 4.36
Revenue 50.73M
Operating Income -121.18M
Net Income -116.11M
Free Cash Flow -41.44M
Net Cash 413.62M
Net Cash / Share 7.04
Gross Margin -128.74%
Operating Margin -238.87%
Profit Margin -228.90%
FCF Margin -81.68%
ROA -17.96%
ROE -36.95%
ROIC -53.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (13)

Buy 7
Overweight 2
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(20.17% upside)
Current: $24.59
Target: 29.55
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth41.63%16.53%58.49%172.65%-
Gross Profit43.1030.4326.1216.486.04
Operating Income-106-90.87-69.56-32.16-13.41
Net Income-99.53-85.34-67.54-31.63-12.40
Shares Outstanding47.2543.0736.0122.220.24
Earnings Per Share-2.11-1.98-1.88-1.42-51.02
Operating Cash Flow-103-61.26-65.2836.11-1.76
Capital Expenditures-6.79-6.23-10.09-6.17-2.55
Free Cash Flow-110-67.48-75.3729.94-4.32
Cash & Equivalents28031434127375.82
Total Debt18.38----
Net Cash / Debt26131434127375.82
Book Value270278301210-21.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Intellia Therapeutics, Inc.
Country United States
Employees 270
CEO John M. Leonard

Stock Information

Ticker Symbol NTLA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NTLA
IPO Date May 6, 2016


Intellia Therapeutics, a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.